BioSpectrum
Taiwan's Senhwa Biosciences inks immunotherapy deal with US biotech firm CellType
Mar 04, 2026To accelerate the evolution of CX-4945 into Version 2.0 and reshape the global immunotherapy landscape
image credit- shutterstock
Taiwan-based Senhwa Biosciences, Inc. has announced the signing of a major strategic Memorandum of Understanding (MoU) with CellType, an artificial intelligence (AI)-driven biotech company backed by Y Combinator (Winter 2026).
Under this partnership, the two companies will integrate CellType's proprietary AI platform to accelerate the clinical development and global commercialisation strategy of Senhwa's core asset, Silmitasertib (CX-4945).
Prior to formalising the collaboration, the foundational research underlying CellType's technology was conducted at Yale University in collaboration with Google DeepMind, where researchers computationally predicted and experimentally validated a novel immune-modulatory mechanism of CX-4945. This strategic alliance marks a transformative milestone for Senhwa: CX-4945 is evolving from a single-target small molecule into a platform-enabling asset—"CX-4945 2.0."
Through AI-driven deep data validation, Senhwa aims to expand potential indications, significantly enhance clinical success probability, and strengthen the asset's attractiveness for partnerships with international pharmaceutical companies for licensing discussion.
In parallel, CellType will feature CX-4945 as the flagship case study of its AI platform, showcasing real-world validation results to global investors—demonstrating how AI can fundamentally transform traditional drug development models, reduce R&D risk, and amplify therapeutic value.
This collaboration not only positions CX-4945 as a core immune-sensitising molecule in immuno-oncology but also establishes Senhwa as CellType's founding strategic partner.